Kintor Pharmaceutical Limited
Kintor Pharmaceutical Limited (HKSE: 9939) is trading at HK$1.76, about ₹22 at today's HKD/INR rate, as of 30 Sep 2026, 4:08 AM ET, down 0.56% today. Indian residents can buy Kintor Pharmaceutical from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
HK$1.75
Today's high
HK$1.81
52 week low
HK$1.60
52 week high
HK$4.70
9939 opened at HK$1.75, closed previously at HK$1.77, and has traded between HK$1.60 and HK$4.70 over the past 52 weeks.
About
Kintor Pharmaceutical Limited, a biotechnology firm in its clinical development phase, is dedicated to the discovery, advancement, and marketing of a diverse array of small molecule and biological therapies. The company primarily concentrates on androgen-receptor-related diseases that represent significant unmet medical needs, serving patients both in the People's Republic of China and globally. Its comprehensive pipeline of investigational products includes: Proxalutamide, a second-generation androgen receptor (AR) antagonist, being explored for the treatment of metastatic castration-resistant prostate cancer, AR-positive breast cancer, and COVID-19. Pyrilutamide, another AR antagonist, is under development for androgenetic alopecia (AGA) and acne vulgaris. An ALK-1 antibody targeting metastatic hepatocellular carcinoma (HCC) and various other solid tumors. GT20029, a topical AR-PROTAC compound, designed to address AGA and acne vulgaris. The dual-target antibody PD-L1/TGF-ß, intended for non-small cell lung cancer, biliary tract cancer, triple-negative breast cancer, and HPV-associated tumors. Detorsertib, which is being investigated for metastatic solid tumors such as breast cancer, prostate cancer, and HCC. A Hedgehog/SMO Inhibitor, an agent that blocks the hedgehog signal transduction pathway, aimed at treating blood cancer and basal-cell carcinoma. Founded in 2009, Kintor Pharmaceutical Limited is headquartered in Suzhou, People's Republic of China.
Key statistics
Avg. volume
978.45K
Market cap
HK$825.27M
P/E Ratio
-3.67
Price-to-sales ratio
9.09
Enterprise value
CN¥843.67M
Free cash flow yield
-20.97%
Debt-to-equity ratio
1.22
Return on equity
-109.54%
ROIC
-66.83%
Beta
-0.56
Dividend yield
0.00%
Last dividend
HK$0.00
Financial overview
Revenue
CN¥32.68M
Earnings per share
-CN¥0.44
Free cash flow
-CN¥166.07M
Net profit margin
-244.44%
Gross margin
12.57%
EBITDA
-CN¥140.66M
Revenue growth
553.64%
Similar securities
This is not an investment recommendation
How to buy Kintor Pharmaceutical from India
Indian residents can buy Kintor Pharmaceutical shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.
Search for Kintor Pharmaceutical and place an order
Find Kintor Pharmaceutical by name or by its ticker, 9939, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. Kintor Pharmaceutical trades 7:00 am – 1:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Kintor Pharmaceutical position in HKD and INR. Kintor Pharmaceutical pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Kintor Pharmaceutical from India
Trading and taxes when buying Kintor Pharmaceutical from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm HKT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneKintor Pharmaceutical does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Kintor Pharmaceutical stock?
Yes. Kintor Pharmaceutical (9939) has been listed on the Hong Kong Stock Exchange since 2020, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Kintor Pharmaceutical share cost in rupees?
One Kintor Pharmaceutical share is HK$1.76 — about ₹22 at an HKD/INR rate of 12.24 on 29 Sep 2026. Both the Kintor Pharmaceutical price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Kintor Pharmaceutical from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of Kintor Pharmaceutical?
Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
How are gains on Kintor Pharmaceutical shares taxed in India?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Kintor Pharmaceutical price. Paasa issues a capital-gains statement for your return.
Does Kintor Pharmaceutical pay a dividend?
No. Kintor Pharmaceutical does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Kintor Pharmaceutical from India?
The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.
Is Kintor Pharmaceutical a Hong Kong SAR China company, and does that change how it is taxed?
Kintor Pharmaceutical trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. Kintor Pharmaceutical trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare Kintor Pharmaceutical shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Kintor Pharmaceutical holding, its cost and its closing value.
How do I sell Kintor Pharmaceutical and bring the money back to India?
You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.